Literature DB >> 2210469

Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate.

T O'Riordan1, E Mathai, E Tobin, D McKenna, C Keane, E Sweeney, C O'Morain.   

Abstract

Persistence of Helicobacter pylori after duodenal ulcer healing is associated with high rates of ulcer relapse. We compared colloidal bismuth subcitrate alone with CBS combined with one of four antibiotic regimens in the treatment of duodenal ulcers. Endoscopy and antral biopsies were performed before treatment and four weeks afterwards. Biopsy specimens were examined for histological evidence of gastritis and by Gram stain and culture for H pylori infection. Altogether 141 patients were allocated to one of five treatment groups. Giving CBS and metronidazole (400 mg tid for 7 days) with and without amoxycillin (500 mg tid) achieved higher clearance rates of H pylori than treatment with CBS alone (p less than 0.01). These two combinations also achieved higher rates of antral gastritis healing than CBS alone (p less than 0.01 and p less than 0.05 respectively). Susceptibility to metronidazole was tested in 29 isolates before and in seven isolates after treatment with metronidazole by disc diffusion test and minimum inhibitory concentration assay. Twenty seven (93%) of the isolates were sensitive before treatment while six of seven (86%) were resistant afterwards. Four of the six resistant strains had acquired resistance during treatment and one of these had acquired metronidazole resistance despite concomitant treatment with amoxycillin, to which it remained sensitive. CBS with adjuvant metronidazole at a dose of 400 mg tid for seven days significantly improves the eradication of H pylori compared with CBS alone. Acquired metronidazole resistance, however, seems to be an important cause of failure to eradicate H pylori.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2210469      PMCID: PMC1378656          DOI: 10.1136/gut.31.9.999

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  14 in total

1.  Unidentified curved bacilli on gastric epithelium in active chronic gastritis.

Authors:  J R Warren; B Marshall
Journal:  Lancet       Date:  1983-06-04       Impact factor: 79.321

2.  Bismuth/ofloxacin combination for duodenal ulcer.

Authors:  E Bayerdörffer; T Simon; C Bästlein; R Ottenjann; G Kasper
Journal:  Lancet       Date:  1987-12-19       Impact factor: 79.321

3.  Metronidazole versus cimetidine in treatment of gastroduodenal ulcer.

Authors:  M Quintero Diaz; A Sotto Escobar
Journal:  Lancet       Date:  1986-04-19       Impact factor: 79.321

4.  Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial.

Authors:  H Humphreys; S Bourke; C Dooley; D McKenna; B Power; C T Keane; E C Sweeney; C O'Moráin
Journal:  Gut       Date:  1988-03       Impact factor: 23.059

5.  In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori).

Authors:  D L Van Caekenberghe; J Breyssens
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

6.  Twice daily tripotassium dicitrato bismuthate in the treatment of duodenal ulceration.

Authors:  D Hollanders
Journal:  Postgrad Med J       Date:  1986-01       Impact factor: 2.401

Review 7.  The clinical significance of Campylobacter pylori.

Authors:  C P Dooley; H Cohen
Journal:  Ann Intern Med       Date:  1988-01       Impact factor: 25.391

8.  Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies.

Authors:  C S Goodwin; B J Marshall; E D Blincow; D H Wilson; S Blackbourn; M Phillips
Journal:  J Clin Pathol       Date:  1988-02       Impact factor: 3.411

9.  Pyloric Campylobacter infection and gastroduodenal disease.

Authors:  B J Marshall; D B McGechie; P A Rogers; R J Glancy
Journal:  Med J Aust       Date:  1985-04-15       Impact factor: 7.738

10.  Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study.

Authors:  J G Coghlan; D Gilligan; H Humphries; D McKenna; C Dooley; E Sweeney; C Keane; C O'Morain
Journal:  Lancet       Date:  1987-11-14       Impact factor: 79.321

View more
  19 in total

1.  In vitro susceptibilities of Actinobacillus actinomycetemcomitans to a number of antimicrobial combinations.

Authors:  M J Pavicić; A J van Winkelhoff; J de Graaff
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

2.  Helicobacter pylori infection and duodenal ulcer.

Authors:  R V Heatley
Journal:  BMJ       Date:  1991-06-22

3.  Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains.

Authors:  A A van Zwet; J C Thijs; B de Graaf
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 4.  Formulary management of antiulcer drugs: clinical considerations.

Authors:  S L Sankey; L S Friedman
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

5.  Effect of eradication of Helicobacter pylori infection on gastric epithelial cell proliferation.

Authors:  R J Cahill; H Xia; C Kilgallen; S Beattie; H Hamilton; C O'Morain
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

6.  Utilization of time-kill kinetic methodologies for assessing the bactericidal activities of ampicillin and bismuth, alone and in combination, against Helicobacter pylori in stationary and logarithmic growth phases.

Authors:  P E Coudron; C W Stratton
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

7.  Treatment of Helicobacter pylori-associated gastroduodenal disease in children. Clinical evaluation of antisecretory vs antibacterial therapy.

Authors:  C Rosioru; M S Glassman; S H Berezin; H E Bostwick; M Halata; S M Schwarz
Journal:  Dig Dis Sci       Date:  1993-01       Impact factor: 3.199

8.  One-day therapy for treatment of Helicobacter pylori infection.

Authors:  A Tucci; R Corinaldesi; V Stanghellini; G F Paparo; S Gasperoni; G Biasco; O Varoli; M Ricci-Maccarini; L Barbara
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

9.  Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance.

Authors:  M J Buckley; H X Xia; D M Hyde; C T Keane; C A O'Morain
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

10.  Development of a 14C-urea breath test in ferrets colonised with Helicobacter mustelae: effects of treatment with bismuth, antibiotics, and urease inhibitors.

Authors:  A A McColm; J A Bagshaw; C F O'Malley
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.